The substantial downgrade in this year's forecasts casts cau...
The substantial downgrade in this year's forecasts casts caution over Suzhou Zelgen Biopharmaceuticals with slower than industry growth expected.
Time To Worry? Analysts Just Downgraded Their Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHSE:688266) Outlook
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment